Trump Announces Up to 200% Tariffs on Generic Drugs, Prompting Indian Pharma Concerns

Trump unveiled steep U.S. import duties ranging from 100% to 200% on generic medicines, ending a two‑year pause and signaling a major shift in American drug pricing policy.

Indian pharmaceutical sector warned that the combined effect of the new tariffs and ongoing shipping disruptions could cause the industry to miss its 2030 sales target, according to a trade body that highlighted a projected shortfall of several billion dollars.

Industry leaders argued the 200% surcharge is financially unfeasible, saying Indian manufacturers lack the capacity to absorb such costs and may be forced to curtail exports or raise prices for domestic markets.

Indian pharma associations have requested direct engagement with the U.S. administration to discuss mitigation, while some firms adopt a “wait‑and‑watch” approach, noting that the immediate threat appears limited but uncertainty remains high.